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Incomplete reporting has been identified as a major 
source of avoidable waste in biomedical research. Essen-
tial information is often not provided in study reports, 
impeding the identification, critical appraisal, and repli-
cation of studies. To improve the quality of reporting of 
diagnostic accuracy studies, the Standards for Reporting 
of Diagnostic Accuracy Studies (STARD) statement was 
developed. Here we present STARD 2015, an updated list 
of 30 essential items that should be included in every re-
port of a diagnostic accuracy study. This update incorpo-
rates recent evidence about sources of bias and variability 
in diagnostic accuracy and is intended to facilitate the use 
of STARD. As such, STARD 2015 may help to improve 
completeness and transparency in reporting of diagnostic 
accuracy studies.
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sources of bias, applicability concerns, 
and factors facilitating generous inter-
pretation in test accuracy research, 
and second, to make the list easier to 
use. In making modifications, we also 
considered harmonization with other 
reporting guidelines, such as Consol-
idated Standards of Reporting Trials 
(CONSORT) 2010 (11).
A complete description of the up-
dating process and the justification 
for the changes are available on the 
Enhancing the Quality and Transpar-
ency of Health Research (EQUATOR) 
website at http://www.equator-net-
work.org/reporting-guidelines/stard. 
In short, we invited the 2003 STARD 
group members to participate in the 
updating process, nominate new mem-
bers, and comment on the general 
scope of the update. Suggested new 
members were contacted. As a result, 
the STARD group has now grown to 
85 members that include researchers, 
editors, journalists, evidence synthe-
sis professionals, funders, and other 
stakeholders.
STARD group members were then 
asked to suggest, and later to endorse, 
proposed changes in a 2-round web-
based survey. This served to prepare 
a draft list of essential items, which 
was discussed in the steering commit-
tee in a 2-day meeting in Amsterdam 
in September 2014. The list was then 
piloted in different groups: starting and 
advanced researchers, peer reviewers, 
and editors.
The general structure of STARD 
2015 is similar to that of STARD 2003. 
of false-positive and false-negative test 
results varies across settings, depend-
ing on how patients present and which 
tests they have already undergone. Un-
fortunately, many authors also fail to 
completely report the clinical context 
and when, where, and how they identi-
fied and recruited eligible study partic-
ipants (8). In addition, sensitivity and 
specificity estimates can differ owing 
to variable definitions of the reference 
standard against which the test is be-
ing compared. Thus this information 
should be available in the study report.
The 2003 STARD Statement
To assist in the completeness and trans-
parency of reporting diagnostic accu-
racy studies, a group of researchers, 
editors, and other stakeholders devel-
oped a minimum list of essential items 
that should be included in every study 
report. The guiding principle for devel-
oping the list was to select items that, if 
described, would help readers to judge 
the potential for bias in the study and 
appraise the applicability of the study 
findings and the validity of the authors’ 
conclusions and recommendations.
The resulting Standards for Re-
porting Diagnostic Accuracy Studies 
(STARD) statement appeared in 2003 
in two dozen journals (9). It was ac-
companied by editorials and commen-
taries in several other publications and 
endorsed by many more.
Since the publication of STARD, 
several evaluations have pointed to 
small but statistically significant im-
provements in reporting accuracy stud-
ies (mean gain 1.4 items; 95% CI 0.7 
to 2.2) (5,10). Gradually, more of the 
essential items are being reported, but 
the situation remains far from optimal.
Methods for Developing STARD 2015
The STARD steering committee peri-
odically reviews the literature for po-
tentially relevant studies to inform a 
possible update. In 2013, the steering 
committee decided that the time was 
right to update the checklist.
Updating had 2 major goals: first, 
to incorporate recent evidence about 
Published online ahead of print
10.1148/radiol.2015151516 Content code: 
Radiology 2015; 277:826–832
Abbreviations:
CONSORT = Consolidated Standards of Reporting Trials
EQUATOR = Enhancing the Quality and Transparency of 
Health Research
IMRAD = Introduction, Methods, Results, and Discussion
STARD = Standards for Reporting Diagnostic Accuracy 
Studies
TRIPOD = Transparent Reporting of a Multivariable Predic-
tion Model for Individual Prognosisor Diagnosis
Conflicts of interest are listed at the end of this article.
As researchers, we talk and write about our studies, not just be-cause we are happy—or disap-
pointed—with the findings, but also to 
allow others to appreciate the valid-
ity of our methods, to enable our col-
leagues to replicate what we did, and 
to disclose our findings to clinicians, 
other health care professionals, and 
decision-makers, all of whom rely on 
the results of strong research to guide 
their actions.
Unfortunately, deficiencies in the 
reporting of research have been high-
lighted in several areas of clinical med-
icine (1). Essential elements of study 
methods are often poorly described 
and sometimes completely omitted, 
making both critical appraisal and 
replication difficult, if not impossible. 
Sometimes study results are selectively 
reported, and other times researchers 
cannot resist unwarranted optimism in 
interpretation of their findings (2–4). 
These practices limit the value of the 
research and any downstream products 
or activities, such as systematic reviews 
and clinical practice guidelines.
Reports of studies of medical tests 
are no exception. A growing number of 
evaluations have identified deficiencies 
in the reporting of test accuracy studies 
(5). These are studies in which a test 
is evaluated against a clinical reference 
standard, or gold standard; the results 
are typically reported as estimates of 
the test’s sensitivity and specificity, 
which express how good the test is in 
correctly identifying patients as having 
the target condition. Other accuracy 
statistics can be used as well, such as 
the area under the ROC curve or posi-
tive and negative predictive values.
Despite their apparent simplicity, 
such studies are at risk of bias (6, 7). If 
not all patients undergoing testing are 
included in the final analysis, for exam-
ple, or if only healthy controls are in-
cluded, the estimates of test accuracy 
may not reflect the performance of the 
test in clinical applications. Yet such 
crucial information is often missing 
from study reports.
It is now well established that sen-
sitivity and specificity are not fixed 
test properties. The relative number 
828 radiology.rsna.org n Radiology: Volume 277: Number 3—December 2015
SPECIAL REPORT: STARD 2015: Reporting Diagnostic Accuracy Bossuyt et al
Scope
STARD 2015 replaces the original 
version published in 2003; those who 
would like to refer to STARD are in-
vited to cite this article. The list of es-
sential items can be seen as a minimum 
have been reworded, combined, or (if 
complex) split. A few have been add-
ed (see Table 2 for a summary of new 
items and Table 3 for key terms). A 
diagram to describe the flow of partic-
ipants through the study is now expect-
ed in all reports (Figure).
A 1-page document presents 30 items, 
grouped under sections that follow the 
Introduction, Methods, Results, and 
Discussion (IMRAD) structure of a sci-
entific article (see Table 1). Several of 
the STARD 2015 items are identical to 
the ones in the 2003 version. Others 
Table 1
The STARD 2015 List
Section and Topic No. Item
TITLE OR ABSTRACT
1 Identification as a study of diagnostic accuracy using at least one measure of accuracy (such as sensitivity, specificity, predictive values, 
or AUC)
ABSTRACT
2 Structured summary of study design, methods, results, and conclusions (for specific guidance, see STARD for Abstracts)
INTRODUCTION
3 Scientific and clinical background, including the intended use and clinical role of the index test
4 Study objectives and hypotheses
METHODS
 Study design 5 Whether data collection was planned before the index test and reference standard were performed (prospective study) or after 
(retrospective study)
 Participants 6 Eligibility criteria
7 On what basis potentially eligible participants were identified (such as symptoms, results from previous tests, inclusion in registry)
8 Where and when potentially eligible participants were identified (setting, location and dates)
9 Whether participants formed a consecutive, random or convenience series
 Test methods 10a Index test, in sufficient detail to allow replication
10b Reference standard, in sufficient detail to allow replication
11 Rationale for choosing the reference standard (if alternatives exist)
12a Definition of and rationale for test positivity cut-offs or result categories of the index test, distinguishing pre-specified from exploratory
12b Definition of and rationale for test positivity cut-offs or result categories of the reference standard, distinguishing pre-specified from 
exploratory
13a Whether clinical information and reference standard results were available to the performers/readers of the index test
13b Whether clinical information and index test results were available to the assessors of the reference standard
 Analysis 14 Methods for estimating or comparing measures of diagnostic accuracy
15 How indeterminate index test or reference standard results were handled
16 How missing data on the index test and reference standard were handled
17 Any analyses of variability in diagnostic accuracy, distinguishing pre-specified from exploratory
18 Intended sample size and how it was determined
RESULTS
 Participants 19 Flow of participants, using a diagram
20 Baseline demographic and clinical characteristics of participants
21a Distribution of severity of disease in those with the target condition
21b Distribution of alternative diagnoses in those without the target condition
22 Time interval and any clinical interventions between index test and reference standard
 Test results 23 Cross tabulation of the index test results (or their distribution) by the results of the reference standard
24 Estimates of diagnostic accuracy and their precision (such as 95% confidence intervals)
25 Any adverse events from performing the index test or the reference standard
DISCUSSION
26 Study limitations, including sources of potential bias, statistical uncertainty, and generalisability
27 Implications for practice, including the intended use and clinical role of the index test
OTHER INFORMATION
28 Registration number and name of registry
29 Where the full study protocol can be accessed
M 30 Sources of funding and other support; role of funders
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of response; studies evaluating treat-
ment selection markers; and more. 
We and others have found most of the 
STARD items useful when reporting 
and examining such studies, although 
STARD primarily targets diagnostic ac-
curacy studies.
Diagnostic accuracy is not the only 
expression of test performance, nor 
is it always the most meaningful (12). 
Incremental accuracy from combining 
tests, relative to a single test, can be 
more informative: for example (13). 
For continuous tests, dichotomiza-
tion into test positives and negatives 
may not always be indicated. In such 
cases, the desirable computational 
and graphical methods for express-
ing test performance are different, 
although many of the methodological 
precautions would be the same, and 
STARD can help in reporting the study 
in an informative way. Other reporting 
guidelines target more specific forms 
of tests, such as Transparent Report-
ing of a Multivariable Prediction Model 
for Individual Prognosis or Diagnosis 
(TRIPOD) for multivariable prediction 
models (14).
Although STARD focuses on full 
study reports of test accuracy studies, 
the items can also be helpful when 
writing conference abstracts, includ-
ing information in trial registries, and 
developing protocols for such studies. 
even more journals, and journal orga-
nizations, will promote the use of this 
and comparable reporting guidelines. 
Funders and research institutions may 
promote or mandate adherence to 
STARD as a way to maximize the value 
of research and downstream products 
or activities.
STARD may also be beneficial for 
reporting other studies that evaluate 
the performance of tests. This includes 
prognostic studies, which can classify 
patients on the basis of whether a fu-
ture event happens; monitoring stud-
ies, in which tests are supposed to de-
tect or predict an adverse event or lack 
set, and an informative study report 
will typically present more informa-
tion. Yet we hope to find all applicable 
items in a well-prepared report of a di-
agnostic accuracy study.
Authors are invited to use STARD 
when preparing their study reports. 
Reviewers can use the list to verify that 
all essential information is available in 
a submitted manuscript and suggest 
changes if key items are missing.
We trust that journals that en-
dorsed STARD in 2003 or later will 
recommend the use of this updated 
version and encourage compliance in 
submitted manuscripts. We hope that 
Table 2
Summary of New Items in STARD 2015
Item Rationale
2: Structured abstract Abstracts are increasingly used to identify key elements of study designs and results.
3: Intended use and clinical 
role of the test 
Describing the targeted application of the test helps readers to interpret the implications of reported accuracy estimates.
4: Study hypotheses Not having a specific study hypothesis may invite generous interpretation of the study results and “spin” the conclusions.
18: Sample size Readers want to appreciate the anticipated precision and power of the study and whether authors were successful in recruiting the 
targeted number of participants.
26 & 27: Structured  
discussion
To prevent jumping to unwarranted conclusions, authors are invited to discuss study limitations and draw conclusions keeping in mind 
the targeted application of the evaluated tests (see item 3).
28: Registration Prospective test accuracy studies are trials, and, as such, they can be registered in clinical trial registries, such as ClinicalTrials.gov, 
before their initiation, facilitating identification of their existence and preventing selective reporting.
29: Protocol The full study protocol, with more information about the predefined study methods, may be available elsewhere, to allow more fine-
grained critical appraisal.
30: Sources of funding Awareness of the potentially compromising effects of conflicts of interest between researchers’ obligations to abide by scientific and 
ethical principles and other goals, such as financial ones; test accuracy studies are no exception.
Table 3
Key STARD Terminology
Term Explanation
Medical test Any method for collecting additional information about the current or future health 
status of a patient
Index test The test under evaluation
Target condition The disease or condition that the index test is expected to detect
Clinical reference  
standard
The best available method for establishing the presence or absence of the target 
condition; a gold standard would be an error-free reference standard
Sensitivity Proportion of those with the target condition who test positive with the index test
Specificity Proportion of those without the target condition who test negative with the index 
test
Intended use of the test Whether the index test is used for diagnosis, screening, staging, monitoring, 
surveillance, prediction, prognosis, or other reasons
Role of the test The position of the index test relative to other tests for the same condition (eg, 
triage, replacement, add-on, new test)
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that working more closely with EQUA-
TOR and other reporting guideline de-
velopers will help us to better reach 
shared objectives. We have updated 
the 2003 explanation and elaboration 
document, which can also be found at 
the EQUATOR website. This document 
explains the rationale for each item and 
gives examples.
The STARD list is released under 
a Creative Commons license. This al-
lows everyone to use and distribute the 
work if they acknowledge the source. 
The STARD statement was originally 
reported in English, but several groups 
have worked on translations in other 
languages. We welcome such transla-
tions, which are preferably developed 
by groups of researchers, by use of a cy-
clical development process, with back-
translation to the original language and 
user testing (19). We have also applied 
for a trademark for STARD to ensure 
that the steering committee has the ex-
clusive right to use the word “STARD” 
to identify goods or services.
group welcomes the development of 
such STARD extensions and invites in-
terested groups to contact the STARD 
executive committee before developing 
them.
Other groups may want to develop 
additional guidance to facilitate the use 
of STARD for specific applications. An 
example of such a STARD application 
was prepared for history-taking and 
physical examination (15). Another 
type of application is the use of STARD 
for specific target conditions such as 
dementia (16).
Availability
The new STARD 2015 list and all related 
documents can be found on the STARD 
pages of the EQUATOR website. EQUA-
TOR is an international initiative that 
seeks to improve the value of published 
health research literature by promoting 
transparent and accurate reporting and 
wider use of robust reporting guidelines 
(17,18). The STARD group believes 
Additional initiatives are underway 
to provide more specific guidance for 
each of these applications.
STARD Extensions and Applications
The STARD statement was designed 
to apply to all types of medical tests. 
The STARD group believed that a sin-
gle checklist, for all diagnostic accuracy 
studies, would be more widely dissem-
inated and more easily accepted by 
authors, peer reviewers, and journal 
editors than separate lists for differ-
ent types of tests such as imaging, bio-
chemistry, or histopathology.
Having a general list may necessi-
tate additional instructions for informa-
tive reporting, with more information 
for specific types of tests, specific ap-
plications, or specific forms of analysis. 
Such guidance could describe the pre-
ferred methods for studying and re-
porting measurement uncertainty, 
for example, without changing any of 
the other STARD items. The STARD 
Prototypical STARD diagram to report ﬂow of participants through the study.
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Increasing Value, Reducing Waste
The STARD steering committee is aware 
that building a list of essential items is 
not sufficient to achieve substantial im-
provements in reporting completeness, 
as the modest improvement after intro-
duction of the 2003 list has shown. We 
see this list not as the final product, but 
as the starting point for building more 
specific instruments to stimulate com-
plete and transparent reporting, such 
as a checklist and a writing aid for au-
thors, tools for reviewers and editors, 
instruction videos, and teaching mate-
rials, all based on this STARD list of 
essential items.
Incomplete reporting has been 
identified as one of the sources of 
avoidable waste in biomedical research 
(1). Since STARD was initiated, sev-
eral other initiatives have been under-
taken to enhance the reproducibility of 
research and promote greater trans-
parency (20). Multiple factors are at 
stake, but incomplete reporting is one 
of them. We hope that this update of 
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editors, reviewers, readers, and deci-
sionmakers to collect, appraise, and ap-
ply the evidence needed to strengthen 
decisions and recommendations about 
medical tests. In the end, we are all 
to benefit from more informative and 
transparent reporting: as researchers, 
as health care professionals, as payers, 
and as patients.
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